Ella Ella Ella Eh Eh Eh

[Jkobe Peoples]

A58-year-old female with an acute myocardial infarction (AMI) has a successful percutaneous cardiac intervention (PCI) to a proximal left anterior descending (LAD) lesion in the cath lab. Post procedure she is in cardiogenic shock. The bedside echo shows a severely impaired left ventricle (LV) with preserved right ventricular (RV) contractility and no major valvular pathology. The hospital is out of extracorporeal membrane oxygenation (ECMO consoles) due to the COVID-19 crisis, and the conversation shifts to inserting an Impella.

It is important to note that the AIC automatically adjusts the purge solution rate between 2-30ml/hour to achieve target purge pressure, which can markedly change the systemic heparin dose. If aPTT is in the supratherapeutic range using purge solution alone, a lower concentration of unfractionated heparin (12.5 or 25 IU/ml) can be used.

Femoral artery puncture sites can be managed with direct manual compression, a Perclose suture-mediated closure system, or open surgical repair. An Impella inserted via the aorta or axillary artery at the end of cardiac surgery will require surgical closure.

Large randomised controlled trials are lacking. A number of attempted studies have failed due to poor enrollment. Completed randomised studies were not designed or powered to detect an outcome difference between an Impella and a comparator.

Conflicting data emerges from retrospective studies. A number of retrospective studies using registry data suggest that an Impella is associated with lower morbidity and mortality in patients with cardiogenic shock, particularly in the setting of acute myocardial infarction. Early use is associated with improved survival versus being used as salvage therapy. However, a recent meta-analysis of randomised and observational trials showed no difference between IABP and Impella use in the risk of 30-day mortality among patients with cardiogenic shock. In addition, another recent meta-analysis suggests the introduction of Impella devices for mechanical circulatory support has resulted in increased adverse events and costs.

All case-based scenarios on INTENSIVE are fictional. They may include realistic non-identifiable clinical data and are derived from learning points taken from clinical practice. Clinical details are not those of any particular person; they are created to add educational value to the scenarios.

ella Important Safety Information

The most common side effects of ella (ulipristal acetate) tablets include headache (18%), stomach pain (12%), nausea (12%), menstrual pain (9%), tiredness (6%), and dizziness (5%). ella should not be used if you know or suspected you are pregnant, and ella should not replace a regular method of birth control. If you become pregnant or have lower abdominal pain after taking ella, seek help from a healthcare provider right away as you could have a pregnancy outside the womb (ectopic pregnancy). ella may change when the next period comes. If your period is delayed beyond 1 week, you should be checked for pregnancy. Do not use ella if you are breastfeeding. Do not use ella more than once in a menstrual cycle. After taking ella if you do have sex again in the same cycle, use a reliable barrier method of birth control like condoms until your next period. Using ella with hormonal birth control such as birth control pills can reduce the effectiveness of both drugs to prevent pregnancy. If you are planning to use hormonal birth control, do so no sooner than 5 days after you take ella. Using some medicines and herbs may make ella less effective. Talk to your healthcare provider about all medicines and herbs you are taking before you use ella. ella does not protect against sexually transmitted infection or HIV.

I see a lot of recipes where people don't soak the bread in water, which is the way traditional panzanella is made. I personally sprinkle water+vinegar on the bread to get it wet before I incorporate it to the vegetables.

-panzanella/

The (native) Italian wife of a co-worker made this dish and brought it into the office. I had never heard of it before. It was out of this world delicious! Tried to get the "secret" recipe but she wouldn't give it up. I have searched all over for it ever since and I believe this is exactly it! I ate the whole thing over the course of the day and evening. Delicious!!! Thank you so much!!!

Delicious! My only mistake was using maybe 25% too few tomatoes, so there wasn't quite enough of that fresh juice to soak in. I back filled with oil and vinegar, but more juice would have been better,

I added shredded rotisserie chicken to get some protein in there; a perfect light summer dinner.

After using ella, if a woman wishes to initiate hormonal contraception as a regular method, she can do so, no sooner than 5 days after the intake of ella and she should use a reliable barrier method until the next menstrual period [see Dosage and Administration (2.2), Drug Interactions (7.1 and 7.3) and Clinical Pharmacology (12.2)].

Progestin-containing contraceptives may impair the ability of ella to delay ovulation. Advise women to follow the instructions on the initiation or resumption of hormonal contraceptives after ella intake [see Dosage and Administration(2.2)].

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Drugs or herbal products that induce CYP3A4 decrease the plasma concentrations of ella, and may decrease its effectiveness [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)]. Avoid co-administration of ella and drugs or herbal products such as:

Ella is contraindicated for use during an existing or suspected pregnancy. No signal of concern regarding pregnancy complications was found in postmarketing studies [see Data]. Isolated cases of major malformations in ella-exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. Miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the U.S. background rate for miscarriage. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Ella pregnancy exposure data was collected in the U.S. and Europe from 1999 to 2015 and analyzed post-marketing using data from interventional clinical trials, observational studies and pharmacovigilance reports. Known pregnancy outcomes were available for 462/784 pregnancies in which women received ella at doses of 30 mg or greater during the conception cycle or during pregnancy. Data of pregnancies with known outcome were analyzed prospectively for 272 cases and retrospectively for 190 cases. Pregnancy outcomes included 302 elective abortions (2 for fetal anomalies including 1 with trisomy 21), 63 spontaneous abortions, and 13 ectopic pregnancies. No maternal or fetal deaths were reported. 84 pregnancies continued until birth, with congenital anomalies reported in 5 infants, including 4 major malformations (2/4 with genetic syndromes). Although these data do not allow estimation of the prevalence rate of congenital anomalies associated with inadvertent use of ella in pregnancy or determination of a causal relationship between reported anomalies and ella, they show that ella-exposed pregnancies were not associated with a pattern of increased risk of adverse outcomes.

Ulipristal acetate was administered repeatedly to pregnant rats and rabbits during the period of organogenesis. Embryofetal loss was noted in all pregnant rats and in half of the pregnant rabbits following 12 and 13 days of dosing, at daily drug exposures 1/3 and 1/2 the human exposure, respectively, based on body surface area (mg/m2). There were no malformations of the surviving fetuses in these studies. Adverse effects were not observed in the offspring of pregnant rats administered ulipristal acetate during the period of organogenesis through lactation at drug exposures 1/24 the human exposure based on AUC. Administration of ulipristal acetate to pregnant monkeys for 4 days during the first trimester caused pregnancy termination in 2/5 animals at daily drug exposures 3 times the human exposure based on body surface area.

The breast milk of 12 lactating women following administration of ella was collected in 24-hour increments to measure the concentrations of ulipristal acetate and the active metabolite monodemethyl-ulipristal acetate in breast milk. The mean daily concentrations of ulipristal acetate in breast milk were 22.7 ng/mL [0-24 hours], 2.96 ng/mL [24-48 hours], 1.56 ng/mL [48-72 hours], 1.04 ng/mL [72-96 hours], and 0.69 ng/mL [96-120 hours]. The mean daily concentrations of monodemethyl-ulipristal acetate in breast milk were 4.49 ng/mL [0-24 hours], 0.62 ng/mL [24-48 hours], 0.28 ng/mL [48-72 hours], 0.17 ng/mL [72-96 hours], and 0.10 ng/mL [96-120 hours]. Using these data, a fully breastfed infant would receive approximately 4.1 mcg/kg of ulipristal acetate and monodemethyl-ulipristal acetate on Day 1 following drug administration and approximately 5.2 mcg/kg over a five day period following drug administration.

3a8082e126